Transient ischemic attack in a patient with congenital protein-C deficiency during treatment with stanozolol

A patient with congenital protein-C deficiency was treated with stanozolol for 8 weeks to increase circulating levels of protein C. A rise in protein C was achieved, accompanied by an increase in factor II, factor X, antithrombin III, and protein S; but at the 8th week the patient suffered a transient ischemia attack.     

Pityriasis rubra pilaris (PRP): report of four cases

Four patients with pityriasis rubra pilaris are reported. The diagnosis in each was based upon well-recognized clinical features. Two of them, a mother and son, had the disease since childhood and were marked by relative remission in spring and exacerbation in autumn. Moderate to severe pruritus was a common dominator. Erythroderma was a presenting feature in one case. Although histopathology was considered imperative, it only supplemented the clinical expression. Vitamin A in heavy dosage, supplemented by vitamin E and stanozolol in tandem, was the mainstay of treatment.     

Stanozolol-N-glucuronide metabolites in human urine samples as suitable targets in terms of routine anti-doping analysis

The exogenous anabolic-androgenic steroid (AAS) stanozolol stays one of the most detected substances in professional sports. Its detection is a fundamental part of doping analysis, and the analysis of this steroid has been intensively investigated for a long time. This contribution to the detection of stanozolol doping describes for the first time the unambiguous proof for the existence of 17-epistanozolol-1′N-glucuronide and 17-epistanozolol-2′N-glucuronide in stanozolol-positive human urine samples due to the access to high-quality reference standards. Examination of excretion study samples shows large detection windows for the phase-II metabolites stanozolol-1′N-glucuronide and 17-epistanozolol-1′N-glucuronide up to 12 days and respectively up to almost 28 days. In addition, we present appropriate validation parameters for the analysis of these metabolites using a fully automatic method online solid-phase extraction (SPE) method already published before. Limits of identification (LOIs) as low as 100 pg/ml and other validation parameters like accuracy, precision, sensitivity, robustness, and linearity are given.     

顶空气相色谱法测定司坦唑醇原料药中溶剂残留量

目的 采用顶空气相色谱法同时测定司坦唑醇原料药中甲醇、乙醇、乙醚、丙酮、异丙醇、乙腈、二氯甲烷、正己烷、正丙醇、乙酸乙酯、四氢呋喃、环己烷和甲苯共13种溶剂残留量.方法 采用顶空气相色谱法,色谱柱为DB-624毛细管柱(30 m x 0.25 mm,3.0 μm),程序升温,进样口温度为200 ℃,检测器为氢火焰离子化...     

司坦唑醇对雌激素受抑的青春期大鼠生长板 软骨细胞生长和成熟的影响

 【目的】 探讨司坦唑醇(ST)对离体培养的促性腺激素释放激素拟似物(GnRHa)处理后青春期大鼠生长板软骨细胞的增殖和分化的影响&#65377; 【方法】 将6只经GnRHa 处理后雌鼠的原代软骨细胞分为时效组(观察ST干预时限的影响)&#65380;量效组(观察ST干预剂量的影响)&#65377;时效组和量效组中,又分为ST干预时效组,对照时效组;ST干预量效组,对照量效组&#65377;通过噻唑兰比色分析法(MTT)法和免疫组化法检测软骨细胞核增殖细胞核抗原(PCNA)&#65380;胞浆中Ⅱ型胶原&#65380;Ⅹ型胶原的表达&#65377;【结果】 (1)对MTT&#65380;PCNA的影响改变 ①时效组:ST 作用后1 天2参数已有显著升高(P < 0.05),并与基值比较,第2 天时达峰(P < 0.001)&#65377;但第4下降至与0 天时比较无差异(P > 0.05)&#65377;②量效组:低浓度的ST无显著促增殖效应(P > 0.05),而浓度增加至10-9 mol/L时促增殖效应显现(P < 0.01),进一步加大ST 浓度至10-5 mol/L,促增殖效应又开始减弱&#65377;(2)对软骨细胞胶原Ⅱ&#65380;Ⅹ合成的影响: ①时效组:ST作用3 d后胶原Ⅱ的表达明显高于对照组(P < 0.05),但至第5 天却表达显降&#65377;ST 作用3 d内胶原Ⅹ分泌量与对照组比较无差异,4 d起显著递增(P < 0.001)&#65377;②量效组:ST各个浓度点的软骨细胞胶原Ⅱ表达较基值均明显增加(P < 0.01),并以10-9 mol/L 最显&#65377;10-11 mol/L ~ 10-8 mol/L 的ST不增加胶原Ⅹ表达,至10-7 mol/L 始随剂量增加而增,10-5 mol/L 时达最高值(P < 0.01)&#65377;量&#65380;时效影响Ⅹ型胶原表达增加均迟于Ⅱ型,作用呈错峰性改变&#65377;【结论】 ST以时效和量效作用方式分别对雌激素受抑的离体青春期大鼠生长板软骨细胞的增殖呈双相影响,在合适的剂量和时间时,细胞增殖效应可达最好效果&#65377;     

复方脑复康预防大鼠去卵巢后骨质疏松的研究

目的:探讨复方脑复康防治去卵巢后骨质疏松的效果.方法:4月龄Sprague-dawley (SD)雌性大鼠38只随机分为5组:基础组,6只,于实验前取材;假手术组,8只,给予生理盐水灌胃;去卵巢组,8只,去卵巢后给予生理盐水灌胃;已烯雌酚组,8只,去卵巢后给予已烯雌酚30 μg/(kg·d)灌胃;复方脑复康组,8只,去...     

雄激素治疗114例获得性非重型再生障碍性贫血患儿疗效分析

为分析雄激素治疗儿童获得性非重型再生障碍性贫血(non-severe aplastic anemia,NSAA)的疗效,本研究回顾性分析1996年1月-2009年1月在我院治疗的114例NSAA患儿临床资料。所有患儿均接受了康力龙0.1mg/(kg.d)治疗。结果表明,15例(13.2%)患儿在中位时间12个月(2-72个月)获得了完全缓解;6例(5.3%)患儿在中位时间19个月(6-72个月)进展为重型再生障碍性贫血(SAA);其余93例患者(81.6%)仍处于NSAA状态。分析各因素(包括性别、年龄、诊断初期中性粒细胞绝对值(ANC)、网织红细胞绝对(ARC)、血红蛋白,骨髓涂片中粒系/红系比例以及是否有输血依赖)与预后的关系发现,诊断初期伴输血依赖较无输血依赖患者更易进展为SAA(19.2%vs1.1%),两组间差异有统计学意义(p=0.016);诊断初期ARC低于50×109/L或ANC低于0.8×109/L易进展为SAA(8.1%vs0%)(p=0.029);(9.1%vs1.7%)(p=0.034),两者均低的患者更易进展为SAA(12.8%vs1.3%)(p=0.011)。结论 :给予康力龙治疗...     

复方司坦唑醇抗泼尼松性大鼠骨质疏松作用研究

目的　探讨大鼠长期超生理剂量应用糖皮质激素引起的骨质疏松症特点 ,同时观察复方司坦唑醇的防治作用。方法　 2 4只 4月龄SPF级SD♂大鼠随机分为 3组 ,1组为溶剂对照组 (NS组 ) ,2组为泼尼松组 (GC组 ) ,3组为复方司坦唑醇治疗组 (CS组 ) ,所有动物予相应的处理因素进行灌胃 ,每天 1次 ,连续 12wk。实验结束后通过观察胫骨的组织形态学参数变化、骨质含量变化和骨的物理生长指标来判断泼尼松长期超生理剂量应用对大鼠骨代谢的影响以及观察复方司坦唑醇对其防治作用。结果　与NS组比较 ,大鼠予泼尼松灌喂 12wk后骨量显著丢失 ,骨生长受到抑制 (P <0 0 1) ,单位骨重量中Hyp含量显著降低 (P <0 0 5 ) ,但单位骨重量中Ca2 + 含量变化不显著 (P >0 0 5 )。复方司坦唑醇制剂可有效增加泼尼松大鼠骨量 (P <0 0 1)以及对抗泼尼松的骨生长抑制作用。结论　泼尼松灌喂大鼠 12wk后 ,可造成骨质明显丢失 ,其中以骨的HyP丢失显著 ,复方司坦唑醇制剂能有效对抗泼尼松造成的大鼠骨生长抑制和骨质疏松     

山莨菪碱和康力龙合用对60例慢性再障的疗效与实验研究

本文应用山莨菪碱(654-2)和康力龙联合治疗慢性再障60例,总有效率85％,缓解率50％。结果表明654-2具有扩张骨髓血管,血流增快,血窦开放。骨髓容量增加、幼红细胞和巨核细胞增多等作用。实验提示,联合用药有促进造血干细胞和骨髓微环境损害的恢复;其疗效比应用单一药物为佳,并有预防康力龙的肝损害作用。